Cargando…

Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

BACKGROUND: Ixekizumab (IXE) is an interleukin (IL)-17A antagonist approved for the treatment of adults with moderate-to-severe psoriasis. OBJECTIVE: The objective of this study was to determine if the immune response to tetanus and pneumococcal vaccines in healthy subjects administered IXE was noni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez, Elisa V., Bishop, Jessie L., Jackson, Kimberley, Muram, Talia M., Phillips, Diane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696443/ https://www.ncbi.nlm.nih.gov/pubmed/29116597 http://dx.doi.org/10.1007/s40259-017-0249-y

Ejemplares similares

Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects
por: Tay, Lee, et al.
Publicado: (2007)

T cell epitope mapping of secukinumab and ixekizumab in healthy donors
por: Spindeldreher, Sebastian, et al.
Publicado: (2020)

15. Evaluation of Retained Immunity for Tetanus-Diphtheria and Pneumococcal Vaccines in Recipients of Cellular Therapies
por: Angelidakis, Georgios, et al.
Publicado: (2021)

The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity
por: Yu, Rui, et al.
Publicado: (2020)

Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab
por: Zhao, Patricia, et al.
Publicado: (2023)

Tetanus
por: Phillips, Walker S.
Publicado: (1898)

Ixekizumab-induced alopecia areata
por: Eldirany, Sherif A., et al.
Publicado: (2019)

Type II mixed cryoglobulinemia following influenza and pneumococcal vaccine administration
por: Eid, Sabine, et al.
Publicado: (2019)

Pneumococcal Colonization in Healthy Adult Research Participants in the Conjugate Vaccine Era, United Kingdom, 2010–2017
por: Adler, Hugh, et al.
Publicado: (2019)

A Comparison of Subcutaneous with Intravenous and Intrathecal Administration of Tetanus Antitoxin in Experimental Tetanus
Publicado: (1918)

The Intrathecal Route for the Administration of Tetanus Antitoxin
Publicado: (1918)

Generalized tinea versicolor following initiation of ixekizumab therapy
por: Alam, Haroon Sayed, et al.
Publicado: (2021)

Influences on Formation of Tetanus Antibody after Simultaneous Injection of Tetanus Immunoglobulin with Tetanus Vaccine
por: Shin, Jonghwan, et al.
Publicado: (2012)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

Pyoderma gangrenosum in a patient on ixekizumab
por: Pollack, Ilana R., et al.
Publicado: (2021)

Ixekizumab‐induced urticarial drug eruption
por: Kaneoka, Ayaka, et al.
Publicado: (2023)

A case of pediatric psoriasis successfully and rapidly treated with ixekizumab
por: Megna, Matteo, et al.
Publicado: (2021)

Pneumococcal-vaccine/tetanus-vaccine/tozinameran: Exacerbation of AQP4 antibody positive acute longitudinal extensive transverse myelitis: case report
Publicado: (2022)

Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein – conjugated pneumococcal vaccine in Filipino infants
por: Capeding, Maria Z Rosario, et al.
Publicado: (2003)

Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP)
por: Klett-Tammen, Carolina J., et al.
Publicado: (2016)

Pneumococcal Nasopharyngeal Carriage in Young Healthy Children After Pneumococcal Conjugate Vaccine in Turkey
por: Arvas, Ahmet, et al.
Publicado: (2017)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
por: Mackenzie, Grant A., et al.
Publicado: (2022)

Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in ≥ 50-year-old adults
por: Song, Joon Young, et al.
Publicado: (2018)

Severe de novo Ulcerative Colitis following Ixekizumab Therapy
por: Philipose, Jobin, et al.
Publicado: (2018)

New onset severe ulcerative colitis following Ixekizumab therapy
por: Morosanu, Alina Mihaela, et al.
Publicado: (2022)

An 80-year-old female with double positive disease: Case report and brief review of literature
por: Almouradi, Tarek, et al.
Publicado: (2013)

Association of Pneumococcal Conjugate Vaccine Coverage With Pneumococcal Meningitis: An Analysis of French Administrative Areas, 2001–2016
por: Alari, Anna, et al.
Publicado: (2019)

Low Influenza, Pneumococcal and Diphtheria–Tetanus–Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren’s Syndrome: A Cross-Sectional Study
por: Jacques, Morel, et al.
Publicado: (2019)

Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children
por: Yung, Chee Fu, et al.
Publicado: (2019)

Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab
por: Hanfstingl, Kathrin, et al.
Publicado: (2018)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
por: Lobo, Yolanka, et al.
Publicado: (2020)

Ixekizumab May Improve Renal Function in Psoriasis
por: Amoruso, Giuseppe Fabrizio, et al.
Publicado: (2021)

The role of ixekizumab in non-radiographic axial spondyloarthritis
por: San Koo, Bon, et al.
Publicado: (2021)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Predictors of Influenza and Pneumococcal Vaccination Among Participants in the Women’s Health Initiative
por: Fix, Jonathan, et al.
Publicado: (2022)

Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
por: Liu, Ya‐ting, et al.
Publicado: (2022)

Outcome of Severe Bacterial Pneumonia in the Era of Pneumococcal Vaccination
por: del Rosal, Teresa, et al.
Publicado: (2020)

153. The Effect of Timing of Tetanus–Diphtheria and Pertussis Vaccine Administration in Pregnancy on The Avidity of Pertussis Antibodies
por: Raya, Bahaa Abu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_emjnpgb98fbr0bdf6l1t49tg5l